A New Me: Chimeric Antigen Receptor (CAR) T-cell Therapy
Michelle She, PharmD
PGY2 Oncology Pharmacy Resident, LLUSP
CAR T-cell therapy is a novel and effective approach for cancer treatment, especially for relapsed or refractory patients with limited treatment options. Given the first FDA approval of CAR T-cell therapy agents in 2017, there is still much to learn regarding this treatment to ensure patients are receiving efficacious and safe treatment. This course will help provide information on what CAR T-cell therapy is, how it is utilized in treatment of hematologic malignancies, and how to manage a patient receiving CAR T-cell therapy, in order to inform participants of current recommended practice strategies. It will also review literature to demonstrate efficacy of CAR T-cell therapy and its utilization in managing patients.